Sector: Health Technology Industry: Biotechnology Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
Market Capitalization 115.522M
Total Shares Outstanding (MRQ) 54.236M
Net Debt (MRQ) -56.821M
Total Assets (MRQ) 97.745M
Revenue per Employee (TTM) 9518.5185
Free Cash Flow (TTM) -39.883M :(, but it's BIO and other indicators look good.
Phase 2-3 trials, FDA looking at turning decision from June that scared off investors.